Exceptional Clinical Response to Alectinib in Pancreatic Acinar Cell Carcinoma With a Novel ALK-KANK4 Gene Fusion
- PMID: 35005993
- PMCID: PMC8769132
- DOI: 10.1200/PO.21.00400
Exceptional Clinical Response to Alectinib in Pancreatic Acinar Cell Carcinoma With a Novel ALK-KANK4 Gene Fusion
Conflict of interest statement
Figures
References
-
- Melisi D, Calvetti L, Frizziero M, et al. : Pancreatic cancer: Systemic combination therapies for a heterogeneous disease. Curr Pharm Des 20:6660-6669, 2014 - PubMed
-
- Wisnoski NC, Townsend CM Jr, Nealon WH, et al. : 672 patients with acinar cell carcinoma of the pancreas: A population-based comparison to pancreatic adenocarcinoma. Surgery 144:141-148, 2008 - PubMed
-
- Holen KD, Klimstra DS, Hummer A, et al. : Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors. J Clin Oncol 20:4673-4678, 2002 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
